Inhibition of the Endogenous GIP Response With a GIP Receptor Antagonist

University Hospital, Gentofte, Copenhagen18 enrolled

Overview

Delinieation of GIP's effects during an oral glucose tolerance test (OGTT) in humans using GIP receptor antagonisation.

Aim: To evaluate the role of GIPR signalling in postprandial physiology, including bone and glucose homeostasis, using a naturally occurring GIP fragment (GIP-A), which antagonises the GIPR. Eighteen healthy men (age 18-70 years, BMI 19-35 kg/m2) with normal kidney and liver parameters and haemoglobin levels and no first-degree relatives with type 2 diabetes will be included in a randomised, double-blinded, placebo-controlled cross-over study. Study consists of four study days with concomitant infusions of A) GIP-A, B) GLP-1 receptor antagonist Exendin\[9-39\], C) GIP-A + Exendin\[9-39\], or D) saline (placebo).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

TRIPLE

Enrollment

Conditions

Glucose Metabolism Disorders

Interventions

GIP-AOTHER

GIP-A (GIP receptor antagonist)

GLP-1 receptor antagonist Exendin[9-39]OTHER

Exendin\[9-39\]

PlaceboOTHER

Saline (9mg/mL)

GIP-A + Exendin[9-39]

Eligibility

Sex: MALEMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Normal kidney function, liver function and hemoglobin levels. Exclusion Criteria: * Medication, Diabetes type 1 or 2, first degree relatives with Diabetes type 2

Locations (1)

Center for Diabetes Research

Gentofte Municipality, Copenhagen, Denmark

Outcomes

Primary Outcomes

Insulin levels

Serum insulin AUC (area under the curve)

Time frame: 240 minutes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.